Miranda McLaren

2 weeks ago | clinicaltrialsarena.com | Miranda McLaren

Melissa Peirsel is the Manager of IRT Services at Sharp and brings over 13 years of experience in clinical trial operations. Her career began in the United States Air Force, where she specialized in managing electronic technology systems. Today, she leads the successful delivery of IRT solutions from Sharp’s Bethlehem, Pennsylvania office, helping sponsors navigate the complexities of modern trial design with practical, system-driven insights.

2 weeks ago | offshore-technology.com | Miranda McLaren

Per- and polyfluoroalkyl substances (PFAS) have been used to create products in just about every industry since the 1950s. Found in everything from carpets and clothing to food packaging, cosmetics, and fire extinguishing foam, the synthetic chemicals are ubiquitous. However, growing sustainability concerns challenge the dominance of PFAS, with some research  suggesting that exposure to certain PFAS materials may result in negative health outcomes.

3 weeks ago | clinicaltrialsarena.com | Miranda McLaren

When preparing for an upcoming drug development program, leveraging existing knowledge and strategies to streamline the process from concept to market is essential. One effective approach is platform development, which utilizes pre-established formulations, analytical methods, and manufacturing processes. This strategy provides a flexible foundation for multiple products, helping teams build on successful systems.

4 weeks ago | offshore-technology.com | Miranda McLaren

In the energy sector, compressing gases and liquids facilitates easier storage, transportation, and processing. The average operating temperature of an industrial compressor used in oil and gas applications is typically between 93°C to 200°C (200°F-400°F), though this can depend on a range of factors such as ambient conditions, compression ratio, and the equipment’s size and efficiency.

1 month ago | pharmaceutical-technology.com | Miranda McLaren

Cell and gene therapies (CGTs) have established themselves as revolutionary treatment methods in the world of oncology, where they have transformed prospects for patients with haematological malignancies. Remarkable results achieved in conditions such as acute lymphoblastic leukaemia and non-Hodgkin’s lymphoma have set a high benchmark for medical breakthroughs, but recent years have witnessed a surge of interest and success in a wider array of previously untreatable conditions.